A Reversal for Antares Pharma Inc (NASDAQ:ATRS) Is Not Near. The Stock Has Rise in Shorts

November 10, 2018 - By Alfred Lee

Investors sentiment increased to 1.41 in Q2 2018. Its up 0.61, from 0.8 in 2018Q1. It increased, as 9 investors sold Antares Pharma, Inc. shares while 20 reduced holdings. 15 funds opened positions while 26 raised stakes. 59.50 million shares or 6.29% more from 55.98 million shares in 2018Q1 were reported.
Goldman Sachs Grp Inc Inc Inc reported 107,043 shares stake. Tiaa Cref Lc holds 0% or 315,629 shares. Alliancebernstein Lp stated it has 85,300 shares. Ameritas Inv Ptnrs invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Wells Fargo Mn holds 2.00 million shares or 0% of its portfolio. Service Automobile Association, a Texas-based fund reported 405,261 shares. Amalgamated Bank reported 22,299 shares or 0% of all its holdings. Chevy Chase Tru Holdings has 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS). Principal Fincl Grp Inc holds 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 59,316 shares. 229,345 were reported by Deutsche Bancorporation Ag. Lpl Lc accumulated 31,191 shares. Citadel Ltd invested in 37,720 shares. Legal & General Gp Pcl has 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS). Boothbay Fund Limited Liability stated it has 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). 100,000 are held by Value Cap Lc.

Since May 14, 2018, it had 0 insider purchases, and 10 selling transactions for $3.18 million activity. APPLE ROBERT F also sold $161,250 worth of Antares Pharma, Inc. (NASDAQ:ATRS) shares.

The stock of Antares Pharma Inc (NASDAQ:ATRS) registered an increase of 9.57% in short interest. ATRS’s total short interest was 6.33 million shares in November as published by FINRA. Its up 9.57% from 5.77M shares, reported previously. With 1.86M shares average volume, it will take short sellers 3 days to cover their ATRS’s short positions. The short interest to Antares Pharma Inc’s float is 4.77%.

The stock increased 0.83% or $0.03 during the last trading session, reaching $3.64. About 1.24M shares traded. Antares Pharma, Inc. (NASDAQ:ATRS) has risen 10.07% since November 10, 2017 and is uptrending. It has underperformed by 5.55% the S&P500.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $573.07 million. The companyÂ’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

More notable recent Antares Pharma, Inc. (NASDAQ:ATRS) news were published by: Nasdaq.com which released: “Detailed Research: Economic Perspectives on Kohl’s, Activision Blizzard, Amerco, Cree, Antares Pharma, and Uranium …” on October 24, 2018, also Nasdaq.com with their article: “Antares Pharma Announces Data Presentation at the 2018 Sexual Medicine Society Scientific Annual Meeting” published on November 09, 2018, Nasdaq.com published: “Antares Pharma to Present at the Jefferies 2018 Global Healthcare Conference” on November 08, 2018. More interesting news about Antares Pharma, Inc. (NASDAQ:ATRS) were released by: Globenewswire.com and their article: “Antares Pharma Reports Third Quarter 2018 Operating and Financial Results” published on November 06, 2018 as well as Nasdaq.com‘s news article titled: “Antares Pharma to Report Third Quarter 2018 Financial and Operating Results” with publication date: October 30, 2018.

Antares Pharma, Inc. (NASDAQ:ATRS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: